<DOC>
	<DOCNO>NCT02456948</DOCNO>
	<brief_summary>This study examine antidepressant efficacy minocycline adjunct antidepressant standard treatment es-/citalopram , venlafaxine mirtazapine monotherapy ( AD-ST ) , patient unipolar major depressive disorder ( MDD ) .</brief_summary>
	<brief_title>Adjunct Minocyline Treatment-resistant Depression</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomize , multicenter proof-of-principle trial adjunctive minocycline patient unipolar major depressive disorder ( MDD ) . The study test antidepressant efficacy minocycline adjunct antidepressant standard treatment es-/citalopram , venlafaxine mirtazapine monotherapy ( AD-ST ) , patient unipolar major depressive disorder ( MDD ) . The respective AD , non-response document , must stable regimen least 14 day prior inclusion . AD-ST continue throughout trial . Trial medication adjunct oral minocycline 200 mg/day placebo . Response treatment measure via Montgomery-Asberg Depression Rating Scale ( MADRS ) . The total study duration patient 6 week .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Informed consent male female age 18 75 BMI 18 40 inclusive Nonlactating , nonpregnant female childbearing potential must willing use effective contraceptive method All participant must fulfil diagnostic criterion moderate severe MDD accord DSM5 . HAMD17 score least 16 point baseline CGIS score least 4 . ADST must administer sufficient dose least 6 week current episode stable regimen least 14 day prior baseline . Dose duration ADST must verifiable prevalence neurodegenerative disorder prevalence neurological disorder cause depressive symptom prevalence severe , unstable general medical condition , include chronic inflammatory disease rheumatoid arthritis inflammatory bowel disease prevalence psychiatric disorder well explain presence depressive symptom Improvement 50 % HAMD17 score last 14 day prior baseline pregnant nursing woman allow . substance alcohol abuse within past 6 month positive urine drug screen abnormal thyroid function ( euthyroid presentation ) , liver kidney dysfunction history autoimmune disease ( except Hashimotos thyroiditis ) clinically significant laboratory abnormality ( outside normal range ) current medication antiinflammatory substance ( NSAIDs , corticosteroid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>treatment resistant depression</keyword>
	<keyword>inflammation</keyword>
	<keyword>microglia</keyword>
	<keyword>minocycline</keyword>
</DOC>